451 related articles for article (PubMed ID: 18448188)
1. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
2. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
3. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
[TBL] [Abstract][Full Text] [Related]
4. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor expression in invasive thymoma.
Henley JD; Koukoulis GK; Loehrer PJ
J Cancer Res Clin Oncol; 2002 Mar; 128(3):167-70. PubMed ID: 11935304
[TBL] [Abstract][Full Text] [Related]
6. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.
Pan CC; Chen PC; Chiang H
J Pathol; 2004 Mar; 202(3):375-81. PubMed ID: 14991904
[TBL] [Abstract][Full Text] [Related]
7. Expression and mutational status of c-kit in thymic epithelial tumors.
Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation: common in thymic carcinomas, rare in thymomas.
Suzuki M; Chen H; Shigematsu H; Ando S; Iida T; Nakajima T; Fujisawa T; Kimura H
Oncol Rep; 2005 Dec; 14(6):1621-4. PubMed ID: 16273266
[TBL] [Abstract][Full Text] [Related]
9. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
10. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].
Ströbel P; Knop S; Einsele H; Müller-Hermelink HK; Marx A
Verh Dtsch Ges Pathol; 2007; 91():177-86. PubMed ID: 18314613
[TBL] [Abstract][Full Text] [Related]
11. Thymic tumors: relevant molecular data in the clinic.
Girard N
J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S291-5. PubMed ID: 20859122
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
[TBL] [Abstract][Full Text] [Related]
13. Parotid carcinoma: expression of kit protein and epidermal growth factor receptor.
Sørensen KB; Godballe C; de Stricker K; Krogdahl A
J Oral Pathol Med; 2006 May; 35(5):286-91. PubMed ID: 16630292
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
15. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.
Boldrini L; Ursino S; Gisfredi S; Faviana P; Donati V; Camacci T; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4101-8. PubMed ID: 15217946
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
[TBL] [Abstract][Full Text] [Related]
17. Expression of proteasome subunit β5t in thymic epithelial tumors.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
[TBL] [Abstract][Full Text] [Related]
18. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach.
Murakawa T; Tsuda H; Tanimoto T; Tanabe T; Kitahara S; Matsubara O
Pathol Int; 2005 Dec; 55(12):757-65. PubMed ID: 16287490
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
Dorfman DM; Shahsafaei A; Miyauchi A
Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
[TBL] [Abstract][Full Text] [Related]
20. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
